The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Several GLP-1 agonists like Ozempic, Mounjaro and Trulicity are currently in shortage, with the Food and Drug Administration ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Most of Lilly's Mounjaro and Zepbound doses in limited ... class of highly effective diabetes and obesity drugs known as GLP-1 agonists, which suppress appetite and promote a feeling of fullness ...